Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma.

Yousef YA, Halliday W, Chan HS, Héon E, Gallie BL, Dimaras H.

Can J Ophthalmol. 2013 Dec;48(6):524-8. doi: 10.1016/j.jcjo.2013.05.018.

PMID:
24314416
2.

Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.

Mulvihill A, Budning A, Jay V, Vandenhoven C, Heon E, Gallie BL, Chan HS.

Arch Ophthalmol. 2003 Aug;121(8):1120-4.

PMID:
12912689
3.

Hypersensitivity to sub-Tenon's topotecan in fibrin adhesive in patients with retinoblastoma.

Astudillo PP, Durairaj P, Chan HS, Héon E, Gallie BL.

J AAPOS. 2015 Feb;19(1):86-7. doi: 10.1016/j.jaapos.2014.09.018.

PMID:
25727598
4.

Periocular topotecan for intraocular retinoblastoma.

Mallipatna AC, Dimaras H, Chan HS, Héon E, Gallie BL.

Arch Ophthalmol. 2011 Jun;129(6):738-45. doi: 10.1001/archophthalmol.2011.130.

PMID:
21670340
5.

Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma.

Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE.

Am J Ophthalmol. 2006 Aug;142(2):310-5.

PMID:
16876514
6.

Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results.

Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH.

Br J Ophthalmol. 2012 Oct;96(10):1300-3. Epub 2012 Aug 3.

PMID:
22863945
7.

Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).

Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP.

Ophthalmology. 2010 Aug;117(8):1623-9. doi: 10.1016/j.ophtha.2009.12.030. Epub 2010 Apr 9.

PMID:
20381868
8.

Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma.

Schaiquevich P, Ceciliano A, Millan N, Taich P, Villasante F, Fandino AC, Dominguez J, Chantada GL.

Pediatr Blood Cancer. 2013 May;60(5):766-70. doi: 10.1002/pbc.24356. Epub 2012 Sep 28.

PMID:
23024125
9.

Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.

Buitrago E, Del Sole MJ, Torbidoni A, Fandino A, Asprea M, Croxatto JO, Chantada GL, Bramuglia GF, Schaiquevich P.

Exp Eye Res. 2013 Mar;108:103-9. doi: 10.1016/j.exer.2013.01.002. Epub 2013 Jan 16.

PMID:
23333535
10.

Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.

Tsui JY, Dalgard C, Van Quill KR, Lee L, Grossniklaus HE, Edelhauser HF, O'Brien JM.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):490-6. doi: 10.1167/iovs.07-0653.

PMID:
18234990
11.

Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.

Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R.

JAMA Ophthalmol. 2014 Aug;132(8):936-41. doi: 10.1001/jamaophthalmol.2014.414.

PMID:
24789622
12.

Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity.

Marr BP, Dunkel IJ, Linker A, Abramson DH.

Br J Ophthalmol. 2012 Jun;96(6):881-3. doi: 10.1136/bjophthalmol-2011-300517. Epub 2012 Feb 10.

PMID:
22328819
13.

Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.

Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG.

Ophthalmology. 2007 Jan;114(1):162-9. Epub 2006 Oct 27.

PMID:
17070578
14.

Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma.

Van Quill KR, Dioguardi PK, Tong CT, Gilbert JA, Aaberg TM Jr, Grossniklaus HE, Edelhauser HF, O'Brien JM.

Ophthalmology. 2005 Jun;112(6):1151-8.

PMID:
15885791
15.

Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.

Gündüz K, Günalp I, Yalçindağ N, Unal E, Taçyildiz N, Erden E, Geyik PO.

Ophthalmology. 2004 Oct;111(10):1917-24.

PMID:
15465557
16.

Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review.

Abramson DH, Marr BP, Brodie SE, Dunkel I, Palioura S, Gobin YP.

PLoS One. 2012;7(4):e34120. doi: 10.1371/journal.pone.0034120. Epub 2012 Apr 24.

17.

Severe aseptic orbital cellulitis with subtenon carboplatin for intraocular retinoblastoma.

Shah PK, Kalpana N, Narendran V, Ramakrishnan M.

Indian J Ophthalmol. 2011 Jan-Feb;59(1):49-51.

18.

In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans.

Kalita D, Shome D, Jain VG, Chadha K, Bellare JR.

Am J Ophthalmol. 2014 May;157(5):1109-15. doi: 10.1016/j.ajo.2014.01.027. Epub 2014 Feb 4.

PMID:
24503408
19.

A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.

Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP.

Ophthalmology. 2008 Aug;115(8):1398-404, 1404.e1. doi: 10.1016/j.ophtha.2007.12.014. Epub 2008 Mar 14.

PMID:
18342944
20.

Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.

Francis JH, Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Jonna G, Abramson DH.

PLoS One. 2013 Aug 21;8(8):e72441. doi: 10.1371/journal.pone.0072441. eCollection 2013.

Items per page

Supplemental Content

Write to the Help Desk